@article{oai:kanazawa-u.repo.nii.ac.jp:00027385,
 author = {中本, 安成 and 金子, 周一 and 須田, 貴司 and Nakamoto, Yasunari and Kaneko, Shuichi and Fan, Hong and Momoi, Takashi and Tsutsui, Hiroko and Nakanishi, Kenji and Kobayashi, Kenichi and Suda, Takashi},
 issue = {8},
 journal = {Journal of Experimental Medicine},
 month = {Oct},
 note = {A persistent immune response to hepatitis viruses is a well-recognized risk factor for hepatocellular carcinoma. However, the molecular and cellular basis for the procarcinogenic potential of the immune response is not well defined. Here, using a unique animal model of chronic hepatitis that induces hepatocellular carcinogenesis, we demonstrate that neutralization of the activity of Fas ligand prevented hepatocyte apoptosis, proliferation, liver inflammation, and the eventual development of hepatocellular carcinoma. The results indicate that Fas ligand is involved not only in direct hepatocyte killing but also in the process of inflammation and hepatocellular carcinogenesis in chronic hepatitis. This is the first demonstration that amelioration of chronic inflammation by some treatment actually caused reduction of cancer development., 金沢大学がん研究所がん病態制御},
 pages = {1105--1111},
 title = {Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-Fas ligand antibody therapy},
 volume = {196},
 year = {2002}
}